Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Strata Critical Medical (SRTA) Depreciation & Amortization (CF) (2020 - 2025)

Strata Critical Medical (SRTA) has disclosed Depreciation & Amortization (CF) for 6 consecutive years, with $3.0 million as the latest value for Q4 2025.

  • Quarterly Depreciation & Amortization (CF) rose 96.6% to $3.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $8.2 million through Dec 2025, up 37.29% year-over-year, with the annual reading at $8.2 million for FY2025, 37.29% up from the prior year.
  • Depreciation & Amortization (CF) for Q4 2025 was $3.0 million at Strata Critical Medical, up from $1.7 million in the prior quarter.
  • The five-year high for Depreciation & Amortization (CF) was $3.0 million in Q4 2025, with the low at $126000.0 in Q1 2021.
  • Average Depreciation & Amortization (CF) over 5 years is $1.5 million, with a median of $1.7 million recorded in 2023.
  • The sharpest move saw Depreciation & Amortization (CF) skyrocketed 808.73% in 2022, then crashed 30.6% in 2024.
  • Over 5 years, Depreciation & Amortization (CF) stood at $717000.0 in 2021, then skyrocketed by 176.71% to $2.0 million in 2022, then dropped by 8.97% to $1.8 million in 2023, then decreased by 15.28% to $1.5 million in 2024, then surged by 96.6% to $3.0 million in 2025.
  • According to Business Quant data, Depreciation & Amortization (CF) over the past three periods came in at $3.0 million, $1.7 million, and $1.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.